Evidence map›Paper›PMID 32077045›Full record

ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2021

Enteral Stents for Malignant Gastric Outlet Obstruction: Low Reintervention Rates for Obstruction due to Pancreatic Adenocarcinoma Versus Other Etiologies.

Jordan Orr, Robert Lockwood, Anthony Gamboa, James C Slaughter, Keith L Obstein, Patrick Yachimski

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jordan OrrDivision of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, 1660 The Vanderbilt Clinic, 1301 Medical Center Drive, Nashville, TN, 37232-5280, USA. jordan.k.orr@vumc.org.
Robert LockwoodDivision of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, 1660 The Vanderbilt Clinic, 1301 Medical Center Drive, Nashville, TN, 37232-5280, USA.
Anthony GamboaDivision of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, 1660 The Vanderbilt Clinic, 1301 Medical Center Drive, Nashville, TN, 37232-5280, USA.
James C SlaughterDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, 37232-5280, USA.
Keith L ObsteinDivision of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, 1660 The Vanderbilt Clinic, 1301 Medical Center Drive, Nashville, TN, 37232-5280, USA.
Patrick YachimskiDivision of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, 1660 The Vanderbilt Clinic, 1301 Medical Center Drive, Nashville, TN, 37232-5280, USA.
Vanderbilt University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimEnteral stents (ES) have emerged as first-line therapy for the treatment of malignant gastric outlet obstruction (GOO). Stent occlusion arising from tissue ingrowth may require endoscopic or surgical reintervention. The objective of this study was to compare rates of reintervention following palliative ES for patients with GOO due to pancreatic adenocarcinoma (PDAC) versus other malignant etiologies.

methodsPatients who had undergone ES for palliation of malignant GOO between 2009 and 2018 were retrospectively identified and demographic, clinical, and procedural data were collected. Primary outcome was procedural reintervention for recurrent symptomatic GOO following ES placement.

resultsForty-three patients were included in the study cohort. 62.8% (27/43) of patients had PDAC while 37.2% (16/43) of patients had other malignant etiologies. 11.6% (5/43) of patients were alive at follow-up. Thirty-day and 90-day mortality rates were 22.8% and 70.7% for PDAC and 25% and 56.3% for other malignant etiologies, respectively. Seven patients required reintervention for symptomatic GOO: 14.3% (1/7) had PDAC and 85.7% (6/7) had GOO due to other malignancy (P < .01). Ninety-six percent (26/27) of patients with PDAC required no further intervention for GOO prior to death or end of follow-up. On multivariate analysis, patients with PDAC were significantly less likely to require reintervention than patients with other malignant etiologies (OR 0.064, 95% CI 0.01-0.60).

conclusionES offer durable symptom palliation without requirement for reintervention for the overwhelming majority of patients with malignant GOO due to PDAC. Reintervention rates are higher following ES placement for GOO due to other malignant etiologies and future study may be needed to define the optimal palliative intervention for this group of patients.

Indexed as

AdenocarcinomaGastric Outlet ObstructionPancreatic NeoplasmsStomach NeoplasmsHumansPalliative CareRetrospective StudiesStentsTreatment OutcomeEnteral stentMalignant gastric outlet obstruction

Identifiers

PMID32077045
OpenAlexW3006865035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.